Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial.

Bianca E Kavanagh, Lana J Williams, Michael Berk, Alyna Turner, Henry J Jackson, Mohammadreza Mohebbi, Buranee Kanchanatawan, Melanie M Ashton, Chee H Ng, Michael Maes, Lesley Berk, Gin S Malhi, Nathan Dowling, Ajeet B Singh, Olivia M Dean

Journal: Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 2020;42(1):14-21

PMID: 31116261

Free Full Text on PubMed Central View on PubMed

Abstract

OBJECTIVE

This study aimed to determine if personality disorder (PD) predicted functional outcomes in patients with major depressive disorder (MDD).

METHODS

Data (n=71) from a double-blind, randomized, placebo-controlled 12-week trial assessing the efficacy of 200 mg/day adjunctive minocycline for MDD were examined. PD was measured using the Standardized Assessment of Personality Abbreviated Scale. Outcome measures included Clinical Global Impression - Improvement (CGI-I), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Social and Occupational Functioning Scale (SOFAS), and Range of Impaired Functioning (RIFT). Analysis of covariance was used to examine the impact of PD (dichotomized factor [≥ 3] or continuous measure) on the outcome measures-treatment group correlation.

RESULTS

PD was identified in 69% of the sample. After adjusting for age, sex, and baseline scores for each of the outcome measures, there was no significant difference between participants with and without PD on week 12 scores for any of the outcome measures (all p > 0.14).

CONCLUSION

In this secondary analysis of a primary efficacy study, PD was a common comorbidity among those with MDD, but was not a significant predictor of functional outcomes. This study adds to the limited literature on PD in randomized controlled trials for MDD.

CLINICAL TRIAL REGISTRATION

ACTRN12612000283875.

Address: Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia.; Department of Psychiatry, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.; Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia.; Centre of Youth Mental Health, University of Melbourne, Parkville, Australia.; School of Medicine and Public Health, Faculty of Health, University of Newcastle, Callaghan, Australia.; Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Australia.; Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Australia.; Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Department of Psychiatry, The Melbourne Clinic, University of Melbourne, Richmond, Australia.; Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.; The University of Sydney, Faculty of Medicine and Health, Northern Clinical School, Department of Psychiatry, Sydney, Australia.; Academic Department of Psychiatry, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia.; CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia.

DOI: 10.1590/1516-4446-2018-0308

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/antidepressants.html

MeSH Terms: Adult, Aged, Antidepressive Agents, Comorbidity, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Male, Middle Aged, Minocycline, Personal Satisfaction, Personality Disorders, Personality Tests, Placebo Effect, Psychiatric Status Rating Scales, Quality of Life, Self Report, Treatment Outcome